Orchestra BioMed logo

Close

  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • News & Events
  • Contact Us

Our Innovations

BackBeat CNT
™

A patented, intelligent bioelectronic treatment for hypertension

BackBeat Cardiac Neuromodulation Therapy™ is designed to immediately, substantially and persistently lower blood pressure.

  • Technology
  • Data
bioelectronic therapy

Programmable and adjustable bioelectronic therapy that immediately, substantially and persistently lowers blood pressure while simultaneously modulating the autonomic nervous system (ANS).

moderato

Can be delivered using standard rhythm management device hardware, such as dual-chamber pacemaker, utilizing the same implant procedure and lead positions.

Close

Patented Intelligent Bioelectronic Therapy

BackBeat CNT-induced neuromodulation enables immediate, sustained and persistent reduction in blood pressure.

lowers blood pressure

Immediately lowers blood pressure

Utilizing proprietary active, intelligent bioelectronic signaling, BackBeat CNT stimulates the heart to immediately and persistently reduce blood pressure.

maintains lowered blood pressure

Maintains Reduction Over Time

BackBeat CNT-programmed variable pressure patterns modulate ANS Response to maintain lowered blood pressure.

multiple medications

Avoids relying on patient medication adherence or compliance

BackBeat CNT works automatically and in conjunction with antihypertension medications a patient may already be taking.

Leveraging Standard Rhythm Management Devices

Readily incorporated into existing devices and paradigm of care.

readily incorporated

Can be incorporated into existing devices

Can be readily incorporated into existing cardiac rhythm management devices such as pacemakers using standard implant and lead placement techniques.

adaptable

Adaptable to the existing paradigm of care

Rapidly adaptable for hypertensive patients already indicated for a pacemaker.

data-icon

BackBeat CNT™ is supported by strong preclinical and clinical data. It has demonstrated statistically significant reductions in blood pressure in patients with hypertension and an indication for a pacemaker.

Preclinical

Delivery of BackBeat CNT significantly reduced 24-hour systolic and diastolic blood pressures in a canine model. The reduction occurred immediately upon activation of therapy and was maintained for the period that the therapy was active.

Significantly Reduced Blood Pressure

Significantly Reduced Blood Pressure chart


*Data on file

Clinical

BackBeat CNT has shown promising clinical performance in two clinical trials:

MODERATO I, an open-label, single-arm, multi-center, prospective study of 27 patients with persistent hypertension and an indication for a pacemaker demonstrated a substantial reduction in blood pressure sustained out to 2 years.

Results Sustained Out to 2 Years (MODERATO I)

Results Sustained Out to 2 Years chart

3-months of data published in the American Heart Association journal

MODERATO I data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2018

MODERATO II, a prospective, multi-center, randomized, double-blind study of BackBeat CNT vs. Medical Therapy in 47 patients with persistent hypertension and an indication for pacemaker met the primary efficacy and safety endpoints and had a high responder rate despite 88.5% of patients with isolated hypertension.


8.11mmHg

Between Groups Reduction in ASBP


12.3mmHg

Between Groups Reduction in OSBP


0%

MACE*


85%

Responder Rate**


Significant Reduction in ASBP (mmHg) at 6 months†

Significant Reduction in ASBP at 6 months chart

Results were presented during the Breakthrough Science Session at TCT 2019

Significant Reduction in OSBP (mmHg) at 6 Months††

Significant Reduction in OSBP at 6 Months chart

†24-Hours ASBP (mmHg) at 6 months Post-Randomization vs. Week 3 Run-in.

††24-Hours OSBP (mmHg) at 6 Months Post-Randomization vs. Week 4 Run-In

*Major Cardiac Advance Events (MACE) included death, heart failure, clinically significant arrhythmias (i.e., persistent or increased atrial fibrillation, serious ventricular arrhythmias), myocardial infarction, stroke and renal failure in treatment group calculated per patient

**Responder rate: % of patients with reduction in ASBP in the treatment group

BackBeat CNT™ is not approved for commercial use in the US

Orchestra BioMed logo
  • Who We Are
    Our Approach
    Our People
    Careers
  • Our Innovations
    Pipeline
    Therapeutic Areas
    Virtue® SAB
    BackBeat CNT™
    FreeHold Retractors
  • News & Events
  • Contact Us

© 2022 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Disclaimer